Physician profile
James E Roberts
NPI 1083628291
$3,123.74
in general payments reported to CMS, 2019-2025
18 companies · $253 in 2025
The $253 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $550 · 2020: $171 · 2021: $580 · 2022: $469 · 2023: $336 · 2024: $765 · 2025: $253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,353.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,353.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $647.79 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $341.15 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $287.25 | 2022-2025 | Verquvo, Dificid |
| Janssen Pharmaceuticals, INC | $261.31 | 2019-2024 | Xarelto |
| Abbvie INC. | $249.01 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $224.00 | 2022-2024 | Jardiance, Combivent Respimat, Stiolto Respimat |
| Astrazeneca Pharmaceuticals Lp | $221.20 | 2019-2024 | Lokelma, Farxiga |
| E.R. Squibb & Sons, L.L.C. | $154.40 | 2020-2024 | Eliquis, Camzyos |
| Inari Medical, INC. | $133.50 | 2021-2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Biohaven Pharmaceuticals, INC. | $124.93 | 2021 | |
| Integra Lifesciences Corporation | $107.26 | 2024 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Amgen INC. | $93.58 | 2019-2025 | Evenity, Prolia, Tavneos |
| Viatris Specialty LLC | $81.55 | 2025 | Yupelri |
| Alexion Pharmaceuticals, INC. | $78.49 | 2022-2024 | Ultomiris |
| Mylan Specialty L.P. | $48.01 | 2019-2024 | Yupelri |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $32.36 | 2024 | Terlivaz |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.78 | 2025 | Xifaxan |
| Avanir Pharmaceuticals, INC. | $18.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Roberts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.